Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Johnson

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Blood|August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Richard Dillon, Adam Ivey, et al.
Blood|August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AMLJad Othman, Nicola Potter, Sylvie D Freeman, et al.
Public Health Research (Southampton, England)|February 8, 2024
Digital adaptation of the Standing up for Myself intervention in young people and adults with intellectual disabilities: the STORM feasibility studyKatrina Scior, Lisa Richardson, Elizabeth Randell, et al.
The Lancet. Haematology|April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Blood|August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Richard Dillon, Adam Ivey, et al.
Blood|August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AMLJad Othman, Nicola Potter, Sylvie D Freeman, et al.
Public Health Research (Southampton, England)|February 8, 2024
Digital adaptation of the Standing up for Myself intervention in young people and adults with intellectual disabilities: the STORM feasibility studyKatrina Scior, Lisa Richardson, Elizabeth Randell, et al.
The Lancet. Haematology|April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Pageof 5